Funding Details
- Awarder
- Inbox
- Date Award
- May 17, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
Company Info
- Company Description
- Imbria Pharmaceuticals is a clinical stage biotechnology company developing novel therapies for patients with life-altering cardiometabolic disorders. The company focuses on restoring or improving the cell's ability to produce energy in cardiometabolic disorders where energetic impairment is a fundamental contributor to disease pathogenesis, symptoms, and functional deficits.
- Market
- Cardiometabolic diseases
- Location
-
Boston,
MA,
USA
- Coinvestors
- Deep Track Capital, AN Ventures, Catalio Capital Management, Cytokinetics, Inc., RA Capital Management, SV Health Investors
Links